Rosacea Market 2024 Size, Growth Analysis, Share, Key Trends And Forecast To 2033

The rosacea market size has grown rapidly in recent years. It will grow from $1.78 billion in 2023 to $1.95 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to growing awareness of rosacea, increasing access to healthcare, rising disposable incomes, government support for rosacea research and treatment, .

The rosacea market size is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to biologic therapies, demand for personalized medicine, aging population, increasing prevalence of comorbidities. Major trends in the forecast period include minimally invasive and non-invasive treatments for rosacea, digital health technologies, rosacea-specific cosmetics, non-invasive therapies.

Market Overview -
Rosacea is a chronic skin disorder that primarily affects the face and causes reddened skin, flushing and bumps, usually on the cheeks and nose. It typically develops in adulthood and is more common in fair-skinned individuals. Rosacea symptoms include swollen red bumps, visible blood vessels and pus-filled pimples.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12945&type=smp

Rising Skin Disease Prevalence Fuels Growth In The Rosacea Market
The increasing prevalence of skin diseases is expected to propel the growth of the rosacea market going forward. Skin diseases are medical conditions that affect the skin's appearance, structure and function. These conditions can involve the skin, hair, nails and related tissues. Rosacea, a type of inflammation and skin problem, can be caused by various fungal infections, including overgrowth of Candida. Moreover, rosacea has a statistically significant increased risk of skin cancers such as hepatic cancer, non-melanoma skin cancer and breast cancer. For instance, in April 2022, according to the American Academy of Dermatology Association, a US-based non-profit medical specialty association, approximately 9,500 people in the US will be diagnosed with skin cancer daily. Furthermore, in March 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the total number of deaths from fungal infections increased from 5,922 in 2020 to 7,199 in 2021. Therefore, the increasing prevalence of skin diseases is driving the growth of the rosacea market.

Competitive Landscape -
Major players in the rosacea market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Galderma S.A., Dr. Reddy's Laboratories Ltd., Lupin Limited, LEO Pharma A/S, Almirall S.A., Supernus Pharmaceuticals Inc., Taro Pharmaceuticals, Mayne Pharma, Aclaris Therapeutics Inc., Sol-Gel Technologies Ltd., Nestle Skin Health S.A., Foamix Pharmaceuticals.

Innovative Epsolay Cream Revolutionizes Rosacea Treatment
Major companies operating in the rosacea market are integrating their efforts into developing novel products and solutions to sustain their position in the market. For instance, in June 2022, Galderma S.A., a Switzerland-based pharmaceutical company, launched EPSOLAY cream, the first and only topical treatment with microencapsulated benzoyl peroxide (E-BPO) that is scientifically proven to alleviate bumps and blemishes caused by rosacea. EPSOLAY Cream uses Sol-Gel Technology's proprietary, patented technology to encapsulate benzoyl peroxide in a silica-based microcapsule to form a barrier between the medication and the skin surface. This helps to reduce the irritation and dryness that can be associated with traditional benzoyl peroxide treatments.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/rosacea-global-market-report

Key Segments -
The rosacea market covered in this report is segmented -
1) By Type: Erythematotelangiectatic Rosacea; Papulopustular Rosacea; Ocular Rosacea; Phymatous Rosacea
2) By Drug Class: Antibiotics; Alpha Agonists; Retinoid; Corticosteroids; Immunosuppressants; Other Drug Classes
3) By Mode of Administration: Topical; Oral
4) By End-User: Hospitals; Clinics; Retail pharmacies; Online pharmacies

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.